Abstract 2717: Bifunctional fusion protein PDL1sFv/MICAe for cancer immunotherapy

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Abstract 2473: A novel anti-PD-1 and proIL-2 bifunctional fusion protein delivers potent anti-tumor activity via PD-1 checkpoint inhibition and tumor selective IL-2R agonism preferentially on antigen specific T cells2024
2. 2Abstract 4341: A novel αPD-1/αVEGF/IL-21v tri-specific fusion protein exhibits potent antitumor efficacy beyond αPD-1/αVEGF bispecific therapy2026
3. 3Abstract 2361: A PD1-antibody-attenuated IL-2 fusion protein activates immune cells leading to the inhibition of tumor growth in ex vivo human 3D tumor models2024 · 1 citations
4. 4Abstract 4057: Beyond IL-2: The promise of anti PD-1-attenuated IL-2 fusion protein in cancer immunotherapy2024
5. 5Abstract 4344: Interferon-α and PD-1 blockade mutually mask each other in a tumor-activated manner2026